Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 5:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3049–3072 of 185,080 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: NOT program Clear all

Conditions: Atrial Fibrillation
Interventions: 4D ICE Adjunct Imaging; Device
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Transcranial Direct Current Stimulation
Interventions: tDCS-NeuroConn., TMS - Magstim., Sham tDCS; Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Spasticity, Multiple Sclerosis
Interventions: IPX056, Baclofen IR, Placebo IPX056, Placebo IR; Drug
Lead sponsor: Impax Laboratories, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 11
States / cities: Tucson, Arizona • Aurora, Colorado • Tampa, Florida + 8 more

Conditions: Influenza Immunization, Healthy Volunteers
Interventions: Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulation, Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2021-2022 formulation; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months and older
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 2
States / cities: Bardstown, Kentucky • Salt Lake City, Utah

Conditions: Acute Lymphoblastic Leukemia
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Anti-CD19-CAR CMV-specific T-lymphocytes, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Echocardiography, Leukapheresis, Lumbar Puncture, Magnetic Resonance Imaging, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, Multigated Acquisition Scan, Positron Emission Tomography, Transplant Conditioning, X-Ray Imaging; Procedure · Biological · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Duarte, California

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: recombinant human Angiostatin protein, paclitaxel, carboplatin; Drug
Lead sponsor: CASI pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Malignant Melanoma
Interventions: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF); Drug
Lead sponsor: Northern California Melanoma Center; Other
Eligibility: 14 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Diabetes, Obesity
Interventions: Autumn Group, Spring Group; Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 5 Years to 18 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Hematopoietic Neoplasm
Interventions: Dietary intake -Food Frequency Questionnaire, Receptivity to Participating in Diet Interventions; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 99 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Atopic Dermatitis
Interventions: Lebrikizumab, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 85
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • North Little Rock, Arkansas + 67 more

Conditions: Insulin Resistance, Postmenopause
Interventions: metformin, leuprolide injection, placebo pill, placebo injection; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 50 Years to 79 Years · Female only
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pancreatic Cancer
Interventions: Bevacizumab, Capecitabine, Radiotherapy; Drug · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Ketosis Prone Diabetes, Diabetic Ketoacidosis, Severe Hyperglycemia
Interventions: pioglitazone; Drug
Lead sponsor: Emory University; Other
Eligibility: 19 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Rift Valley Fever
Interventions: Inactivated, Dried (TSI-GSD 200), RVF Vaccine; Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2021
U.S. locations: 1
States / cities: Fort Deterick, Maryland

Conditions: Eosinophilic Esophagitis
Interventions: Absorbable sugars; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Osteoporosis, Postmenopausal
Interventions: Experimental: 40 minute up trial, Experimental: 40 minute down trial, Experimental: Two 20 minute up trials, Experimental: Two 20 min down trials, Active Comparator: Sedentary trial; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 50 Years to 65 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Acne Vulgaris
Interventions: Trifarotene; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 9 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 9
States / cities: Fort Smith, Arkansas • Beverly, Massachusetts • Portsmouth, New Hampshire + 6 more

Conditions: Oral Leukoplakia, Oral Dysplasia
Interventions: Mucoadhesive fenretinide-releasing system (FMS); Drug
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Clostridium Difficile
Interventions: Sage 2% Chlorhexidine Gluconate Cloth Patient Preoperative Skin Preparation; Drug
Lead sponsor: Jared Brooks; Other
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Geneva, Illinois

Conditions: Head and Neck Neoplasms, Carcinoma, Squamous Cell
Interventions: Afatinib, Methotrexate; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 483 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 8
States / cities: Harvey, Illinois • Peoria, Illinois • Boston, Massachusetts + 4 more

Conditions: Healthy
Interventions: dark chocolate, non dark chocolate; Dietary Supplement · Other
Lead sponsor: Loma Linda University; Other
Eligibility: 21 Years to 45 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Prostate Cancer
Interventions: 3T Magnetic Resonance Spectroscopic Imaging; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Myeloma
Interventions: DS-3032b; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Obstructive Sleep Apnea (OSA)
Interventions: C-Lift; Device
Lead sponsor: Ata Murat Kaynar; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

Evaluation of 4D Intracardiac Echocardiography (ICE) During Structural Heart and Electrophysiology Procedures

Neurophysiological and Functional Mechanisms of Motor Control and Learning

A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia

Safety and Efficacy Study of rhAngiostatin Administered in Combination With Paclitaxel and Carboplatin to Patients With Non-Small-Cell Lung Cancer

GM-CSF as Adjuvant Therapy of Melanoma

Project Powerfood: Promoting Food Security, Equity, and Health

UF-BMT-HSCT-001: A Non-Interventional Study Evaluating Diet in HSCT Survivors

A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)

Insulin Resistance and Testosterone in Women

Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients With Locally Advanced Pancreatic Cancer

Ketosis Prone Diabetes in African-Americans

Safety and Immunogenicity Study of Rift Valley Fever Vaccine, Inactivated

Intestinal Permeability in Response to Treatment in Eosinophilic Esophagitis Patients

Parameters of Exercise to Prevent Osteoporosis

Participant Reported Outcomes With Use of Trifarotene 50 μg/g Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris

Fenretinide Mucoadhesive Patch: Evaluation of Oral Cancer Prevention Efficacy in Adults With Premalignant Oral Lesions.

Chlorhexidine Bathing Effect on Clostridium Difficile Rates

LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy

The Effects of Dark Chocolate (70% Cacao) on EEG Brain Waves in Vigorously Active Individuals

3T Perfluorocarbon-Filled Endorectal Magnetic Resonance Spectroscopic Imaging of Prostate

Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Relapsed and/or Refractory Multiple Myeloma

C-LIFT Efficacy in Patients With Obstructive Sleep Apnea